CD74 is a cell membrane receptor for macrophage migration inhibitory factor (MIF) that is believed to play a role in tumor progression and metastasis. Astrocytoma is the most common type of brain cancers, which are classified by the World Health Organization (WHO) into four grades according to the degree of malignancy. In this study, we investigated MIF and CD74 gene expression levels in a large cohort of publicly available RNA sequencing data and evaluated the correlation between their protein expression with clinicopathological features as well as prognosis in an independent cohort of astrocytoma samples. Seventy-three patients with different grades of astrocytoma (WHO grade II diffuse astrocytoma, grade III anaplastic astrocytoma, and grade IV glioblastoma) were used for protein expression in this study. The expression of CD74 was assayed by immunohistochemistry and was significantly higher in highgrade glioblastoma than grade II and grade III astrocytoma (P < 0.004). Upregulated CD74 expression was frequently found in older patients (≥ 62 years). The expression of CD74 is correlated with overall survival (P = 0.05). Multivariate analysis shows that the CD74 expression is associated with poor prognosis in the presence of MIF expression (P = 0.039) and that CD74 is not an independent prognostic marker in glioblastoma. However, similar studies on larger sample size are required to make a definite conclusion on the role of CD74 in prognosis in glioblastoma.
INTRODUCTION
Astrocytoma is the most prevalent form of brain tumor (1) . For the year 2012, crude incidence and mortality rate for brain cancers in the Czech Republic were 8.1 and 6.0, respectively. In Olomouc, these rates for the same period were 8.0 and 6.6, respectively. (www.svod.cz). According to the World Health Organization gliomas are divided into four histological grades of increasing malignancy (WHO grade I to WHO grade IV) tightly coupled to patient outcome. Despite advances in the current treatment regimen for patients with diffuse high-grade astrocytoma, which includes surgical resection followed by radio-and chemotherapy, a poor overall survival rate is observed in these cases (1) . This poor prognosis is attributed to uncontrolled tumor proliferation and invasion of surrounding brain parenchyma (2) , and the ability to induce angiogenesis (3) . A number of ongoing studies are focused on finding potential biomarkers and therapeutic targets to improve survival and prognosis in diffuse high-grade astrocytoma. One such biomarker is CD74, a cell membrane receptor for macrophage migration inhibitory factor (MIF) and a potential therapeutic target. CD74 is a non-polymorphic type II integral membrane protein (4) . It functions as an MHC-II chaperone and participates in the trafficking of MHC-II molecules in antigenpresenting cells (5) and also shown to express independently of MHC-II and can bind to non-MHC-II proteins (6) . The binding of MIF to the extracellular domain of CD74 is necessary as an initial step for the MIF signaling cascade. MIF signals upstream of cytokines via receptor binding in CD74-dependent pathways (4) . The pro-inflammatory cytokine MIF and its receptor CD74 (4) are associated with tumor vascularization (7) and the promotion of neoplastic cell proliferation and survival via ERK1/2-MAPK (extracellular signal-regulated protein kinases 1/2 and mitogen-activated protein kinase) pathway (7) . MIF can activate the extracellular signal-regulated kinase phosphorylation via CD74 and CD44, where CD44 activates non-receptor tyrosine kinases (4) . This is thought to enhance tumor growth in several human neoplasms. Furthermore, MIF and CD74 may also act as noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment (8) . MIF and CD74 form complexes with the cysteine-Xcysteine (CXC)-chemokine receptors CXCR2 on myeloid cells and CXCR4 on T cells (8) . The overexpression of MIF and/or CD74 has thought to enhance tumor growth in several human neoplasms, including breast cancer (9) , pancreatic cancer (10) , lung cancer (7) , and thyroid carcinoma (11) . Targeted therapies for CD74 that are currently under investigation includes Milatuzumab, a humanized MAB that recognizes CD74, which was able to stabilize advanced multiple myeloma (12) . Milatuzumab is in phase I clinical trials as a cancer therapy, currently mainly focusing on hematopoietic neoplasms (13) . In this study, we aimed to investigate the prognostic significance of CD74 expression in astrocytoma patients and to evaluate the rationale for further CD74 targeted therapy approaches in gliomas.
METHODS
RNA sequencing data analysis for MIF and CD74 expression We investigated for MIF and CD74 expression using publicly available RNA sequencing data. The original transcriptome analysis of astrocytoma study is accepted for publication. For this study, we reanalysed this data to obtain MIF and CD74 expression in astrocytoma grades II-IV. Raw sequence reads were obtained from GEO (Gene Expression Omnibus; RRID: SCR_005012) in the form of FastQ files. Reads from FastQ files were aligned to human reference sequence hg19 (RRID: SCR_006553) using Rsubread aligner. Mapped sequencing reads were assigned to hg19 refGene using featureCounts (RRID: SCR_012919). RefGene exon coordinates were obtained from UCSC table browser (RRID: SCR_013787). Differentially expressed genes were identified using edgeR (RRID: SCR_012802). Genes with reading count per million > 1 in at least half of the samples were considered for further analysis. The data was normalized using TMM (trimmed mean of M values) method. Immunohistochemistry and evaluation of immunohistochemical findings FFPE sections were cut at 4μm thickness, deparaffinized in xylene, and rehydrated by washing in serial dilutions of ethanol. To unmask antigens, heat antigen retrieval was performed in citrate buffer at pH 6. Endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide for 15 minutes. These sections were incubated overnight at 4°C with the anti-CD74 mouse monoclonal antibody (Sigma-Aldrich c-2955, LN-2) at dilution 1:600 and MIF mouse monoclonal antibody (R&D system MAB289, 12302) at dilution 1:600. Hodgkin's lymphoma samples were used as positive controls for both antibodies. In negative controls, primary antibody was omitted. Antigen was visualized using the EnVision kit (DAKO A⁄ S, Glostrup, Denmark) after incubating sections for 2 min. These slides were then counterstained with hematoxylin and mounted in an aqueous medium. Positive staining for CD74 was defined as membranous and perinuclear staining in brown color, while cytoplasmic staining in brown is considered as positive for MIF. CD74 and MIF protein expression were evaluated semi-quantitatively by two independent pathologists (NN and JE) blinded to the clinical and histological diagnosis. Percentage of positive cells was estimated and scored into 5 categories defined as follows: 0, all negative; 1+, <25% positive cells; 2+, 25-49%; 3+, 50-74%; and 4+, >75%. The intensity of staining was (scored on a scale 0 to 3) also classified into four groups as follows: 0, negative; 1+, weak; 2+, moderate; and 3+, strong. The intensity level observed in the largest number of positive cells was used for scoring. Immunoreactivity score (ranging between 0 and 12) for each case was obtained by multiplying scores from percentage and intensity. Cases were categorized as low expression group (Hara ≤ 6 IRS) and high expression group (Hara > 6 IRS) for statistical analysis.
Statistical analysis
Immunoreactive scores for CD74 were compared according to each of clinicopathological factors (age, gender, grade, and KPS). Nonparametric comparison between independent groups was carried out using the Mann-Whitney and Kruskal-Wallis test. Overall survival rates were examined by using Kaplan-Meier method (P value with the log-rank test). Uni-and multivariate analysis were performed using Cox regression analysis to examine whether the CD74 expression was a prognostic factor independent of other clinicopathological factors. Above analyses were performed using the SPSS software (version 20). P-values <0.05 were considered statistically significant.
RESULTS

CD74 gene expression is increased with increasing tumor grade
We did not find a significant differential expression for MIF in our RNAseq data analysis. However, the CD74 expression has increased with increasing grade in astrocytoma as shown in the Fig. 1.   Fig.(1) 
CD74 protein expression increases with tumor grade progression in astrocytoma
Consolidating our observation of CD74 gene expression analysis, we have observed an increase in the CD74 protein expression with increasing tumor grade (P < 0.004). Association between CD74 expression and clinicopathological parameters of all patients are shown in Table 1 . Statistically significant correlation between the CD74 expression levels and the progression of astrocytoma (P < 0.004) was observed. A significant association between CD74 expression and patient age (median 62 years) was observed (P < 0.003; Table 1 ). However, the expression level of CD74 had no statistically significant association with other parameters, including patient gender, KPS, and surgery.
In support of our observation in the differential gene expression analysis for MIF (data not shown), no significant difference in MIF expression was observed between the tumor grades ( Fig. 2) . No significant correlation between MIF expression and clinicopathological factors was found in this study. In normal human white matter, very few CD74-positive cells with elongated cellular processes were present (Fig. 2) . In contrast to CD74-positive cells in normal tissue, cells expressing CD74 in WHO grades II-IV presented with a more round shape morphology, mainly lacking fine cellular processes. The representative micrographs of IHC from different grades of astrocytoma can be viewed in Fig. 2 . 
Fig.( 2). CD74 and MIF expression in grade II-IV astrocytoma. Very low expression of CD74 was observed in normal brain tissue whereas increased expression of CD74 was seen with increasing astrocytoma grade. MIF expression was absent in normal brain samples, and overexpression MIF was seen in grade II-IV astrocytoma (200X magnification).
To 
CD74 expression is a potential bad prognostic marker in glioblastoma
Kaplan-Meier overall survival (OS) curve (Fig. 3A) of all astrocytoma patients for CD74 expression levels showed patients with high CD74 expression had significantly poorer prognosis compared to those with low or no CD74 expression (log-rank test, P = 0.05).
Our study also found a significant correlation (Fig. 3B ) between high-grade astrocytoma and overall survival rate (log-rank test, P = 0.001) confirming worst prognosis for high-grade astrocytoma.
According to the univariate analysis for different clinicopathological characteristics, including age, gender, MIF expression, CD74 expression, pre-and post-operative KPS score, we found that CD74 expression, age group, preoperative KPS and postoperative KPS score were significantly associated with OS (P = 0.032, P = 0.0001, P = 0.018 and P = 0.0001 respectively; Table 2 ). Furthermore, multivariate logistic analysis showed that age (HR 0.412, 95% CI 0.223-0.762; P = 0.005; Table 2 ) and post-operative KPS score (HR 3.130, 95% CI 1.681-5.829; P = 0.0001; Table 2 ) were statistically independent predictive factors of poorer prognosis in astrocytoma patients, whereas high CD74 expression had a less significant association with poor prognosis alone (CD74 high, HR 1.114, 95% CI 0.995-1.249; P = 0.062; Table 2 ). However, the C74 expression is a statistically independent predictive factor of poor prognosis in multivariable analysis with MIF expression (CD74 high, HR 1.097, 95% CI 1.005-1.197; P = 0.039).
DISCUSSION
To the extent of our knowledge, this current study is the first study to show CD74 expression as a bad prognostic marker in grade II-IV astrocytoma. Ghoochani et al. showed that Macrophage migration inhibitory factor (MIF) activates CD74 and inhibits interferon-γ (IFN-γ) secretion in microglia through phosphorylation of microglial ERK1/2, extracellular signal-regulated protein kinases 1 and 2 (15) . In line with this observation, we demonstrated overexpression of MIF in grade II-IV astrocytoma, and that overexpression of CD74 is associated with tumor progression in astrocytoma at the gene and transcription levels. MIF exerts multimodal functions in glioblastoma including pro-proliferative, promigratory, pro-angiogenic as well as immune-evasive properties through CD74 (16, 17, 18) . The binding of MIF to the extracellular domain of CD74 is necessary as an initial step in the MIF signaling cascade (4) resulting in tumor vascularization and the promotion of neoplastic Fig.(3) cell proliferation and survival via ERK1/2-MAPK pathway (7) . Uni-and multi-variate analysis for CD74 expression in this study revealed a significant association for age, preoperative KPS, and post-operative KPS score, with overall survival, supporting the empirical evidence seen in the majority of the cancers. Although we found statistically significant correlation between CD74 expression and tumor grade in this study, due to lack of enough sample size for each grade, we could not obtain any statistical significance for tumor grade in this study and be excluded from these analyses (data not shown). Age and KPS were considered as biomarkers in preoperative decision making (19) . Postoperative KPS scores have superior predictive capabilities for overall survival in glioblastoma patients and should replace preoperative KPS scores when estimating prognosis (20) . Similar to previous association studies of CD74 expression and survival in other cancers, KaplanMeier overall survival analyses for CD74 expression levels revealed a significant association between high CD74 expression and poorer prognosis (log-rank test, P = 0.05) (7, 10, 11) . Furthermore, our data confirmed worst prognosis for high-grade glioblastoma with high levels of CD74 expression. However, our data suggest that CD74 expression alone is not an independent marker for poor prognosis and it requires the expression of MIF for tumor pathogenesis, as previously reported in other studies (4, 7, 16, 17, 18) . Although we did not perform co-localization staining for MIF-CD74 in this retrospective study, evidence of MIF and CD74 co-localization reported in several other studies (7, 8, 9, 10, 11, 12, 13, 14) .
CONCLUSION
In conclusion, our study highlighted that CD74 could be a potential biomarker for prognosis in conjunction with MIF in glioblastoma patients. However, a major limitation of our retrospective study is relatively small sample cohort of each different grade of astrocytoma.
